CLINICAL TRIALS PROFILE FOR NAPROSYN
✉ Email this page to a colleague
All Clinical Trials for NAPROSYN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00153660 ↗ | Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients | Completed | Chinese University of Hong Kong | Phase 3 | 2005-06-01 | The aim of this study is to compare celecoxib plus a PPI (esomeprazole) versus naproxen plus a PPI (esomeprazole) in preventing recurrent ulcer bleeding in arthritis patients with a history of ulcer bleeding who require concomitant ASA. We hypothesized that among patients with a history of ulcer bleeding who require concomitant ASA, celecoxib plus esomprazole would be superior to naproxen plus esomeprazole for the prevention of recurrent ulcer bleeding. |
| NCT00303017 ↗ | Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study | Completed | Primus Pharmaceuticals | N/A | 2006-03-01 | safety, efficacy and acceptability of Flavocoxid |
| NCT00383487 ↗ | A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer | Terminated | Novacea | Phase 2 | 2005-03-01 | To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls. |
| NCT00383487 ↗ | A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer | Terminated | Stanford University | Phase 2 | 2005-03-01 | To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls. |
| NCT00435292 ↗ | Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee | Completed | Primus Pharmaceuticals | N/A | 2006-04-01 | Randomized, double-blind, placebo controlled parallel group, multi center study in subjects with moderate-severe osteoarthritis. |
| NCT00527787 ↗ | Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen | Completed | POZEN | Phase 3 | 2007-09-01 | This study uses a randomized, double-blind, controlled design to demonstrate that PN400 (esomeprazole and naproxen) is more effective in reducing the occurrence of gastroduodenal ulcers, dyspepsia, and heartburn in subjects at risk for developing NSAID-associated gastric ulcers compared to naproxen alone. |
| NCT00527904 ↗ | A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO) | Completed | POZEN | Phase 3 | 2007-03-01 | This study uses an open-label design and will be conducted in approximately 60 sites aiming to enroll a total number of 200 subjects to ensure that at least 100 subjects will have 12 months exposure to PN400 (VIMOVO). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NAPROSYN
Condition Name
Clinical Trial Locations for NAPROSYN
Trials by Country
Clinical Trial Progress for NAPROSYN
Clinical Trial Phase
Clinical Trial Sponsors for NAPROSYN
Sponsor Name
